首页> 外国专利> use of ranolazine in combination with at least one remodeling agent for reversal of left ventricular remodeling in the treatment of heart failure.

use of ranolazine in combination with at least one remodeling agent for reversal of left ventricular remodeling in the treatment of heart failure.

机译:雷诺嗪与至少一种改型剂联合用于逆转左心室改型在心力衰竭中的应用。

摘要

USE OF RANOLAZINE IN COMBINATION WITH AT LEAST ONE REMODELING AGENT FOR REVERSAL OF VENTRICULAR REMODELING LEFT IN HEART FAILURE TREATMENT. The present invention relates to a method of reversing left ventricular remodeling by combined administration of therapeutically effective amounts of ranolazine and at least one remodeling agent, which may be an ACE inhibitor, an ARB or a beta blocker. The method finds utility in treating heart failure. The present invention also relates to pharmaceutical formulations which are suitable for such combined administration.
机译:兰诺嗪与至少一种重塑剂联合使用可逆转心力衰竭治疗中的左室重塑。本发明涉及通过联合施用治疗有效量的雷诺嗪和至少一种重塑剂来逆转左心室重塑的方法,雷诺嗪和至少一种重塑剂可以是ACE抑制剂,ARB或β阻滞剂。该方法可用于治疗心力衰竭。本发明还涉及适合于这种联合施用的药物制剂。

著录项

  • 公开/公告号BRPI0517650A

    专利类型

  • 公开/公告日2008-10-14

    原文格式PDF

  • 申请/专利权人 CV THERAPEUTICS INC.;

    申请/专利号BR2005PI17650

  • 发明设计人 BRENT BLACKBURN;HANI NAIEF SABBAH;

    申请日2005-11-09

  • 分类号A61K31/495;A61P9;

  • 国家 BR

  • 入库时间 2022-08-21 20:08:44

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号